PRX-07034

PRX-07034 is a drug that was developed for the treatment of obesity and cognitive impairment. It acts as a selective 5-HT6 receptor antagonist. PRX-07034 has been found to produce nootropic effects in animal studies, and reduces food intake and increases metabolism, potentially making it useful for the treatment of obesity.

Pharmacology

PRX-07034 is a potent and selective antagonist for the 5-HT6 receptor. This receptor is one of the several different subtypes of the serotonin receptor, and is thought to play a role in cognition and memory. Antagonism of this receptor by PRX-07034 results in increased release of acetylcholine and glutamate, two neurotransmitters that are important for learning and memory.

Clinical Trials

PRX-07034 has undergone Phase I clinical trials for the treatment of obesity and cognitive impairment. However, the results of these trials have not been published, and the current status of this drug is unknown.

Potential Uses

The primary potential use for PRX-07034 is in the treatment of obesity. By increasing metabolism and reducing food intake, it could help individuals lose weight. Additionally, due to its nootropic effects, it could potentially be used to treat cognitive impairment, including conditions such as Alzheimer's disease and dementia.

See Also

• 5-HT6 receptor
• Obesity
• Cognitive impairment
• Nootropic

PRX-07034 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia